Press release
Neglected Tropical Disease Treatment Market Strategic Insights and Outlook 2026 to 2035
The Neglected Tropical Disease Treatment Market is valued at US$ 2.9 Bn in 2023, and it is expected to reach US$ 4.4 Bn by 2031, with a CAGR of 5.3% during the forecast period of 2024-2031.
Request For Free Sample Report:
https://www.insightaceanalytic.com/request-sample/2928
Neglected Tropical Disease (NTD) treatment comprises a range of medical interventions, including pharmaceutical therapies, vaccination programs, and public health initiatives, aimed at managing infectious diseases that predominantly impact underserved and vulnerable populations. The NTD treatment market is demonstrating notable growth, supported by increased international funding, progress in medical technologies, and heightened global awareness of these conditions. Advancements in diagnostics and therapeutic solutions are improving treatment effectiveness and accuracy, thereby contributing to market expansion.
Furthermore, government-driven awareness and outreach programs are instrumental in informing communities about available treatment options and encouraging the adoption of preventive healthcare practices. At the same time, pharmaceutical and biotechnology companies are making substantial investments in research and development to introduce innovative and more effective treatment approaches. Despite these positive developments, regulatory complexities and the requirement for specialized technical expertise remain key challenges that may constrain overall market growth.
List of Prominent Players in the Neglected Tropical Disease Treatment Market:
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Omega Diagnostics Group PLC
• Abbott
• Oscar Medicare Pvt. Ltd.
• Merck Ltd.
• Genome Diagnostics Pvt. Ltd.
• ZeptoMetrix
• Bayer AG,
• GlaxoSmithKline plc
• Novartis AG
• Pfizer, Inc.
• Eisai Co. Ltd.
• Sanofi
• Astellas Pharma
• Takeda Pharmaceutical Company Limited
• Gilead Sciences
• Other Market Players
Market Dynamics:
Drivers-
The growth of the neglected tropical disease (NTD) treatment market is being propelled by advancements in medical technology, improvements in healthcare infrastructure, strong governmental support, and increasing public awareness. Enhanced initiatives by governments and international health organizations focused on the prevention and eradication of NTDs are further accelerating market development. In addition, the introduction of advanced diagnostic technologies and innovative therapeutic solutions is transforming disease management by improving treatment effectiveness, accessibility, and overall patient outcomes.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2928
Challenges:
The expansion of the NTD treatment market is constrained by several key challenges. Limited funding in endemic and low-income regions restricts the development, production, and distribution of essential therapies. High research and development costs, combined with relatively low financial incentives for pharmaceutical companies, further hinder market progress. Moreover, inadequate healthcare infrastructure in regions most affected by NTDs limits patient access to timely and effective medical interventions.
Regional Trends:
North America is expected to account for a significant share of the NTD treatment market and is projected to grow at a robust compound annual growth rate (CAGR) over the forecast period. This growth is supported by a well-established pharmaceutical sector, advanced healthcare systems, and a favorable regulatory framework, along with the presence of major industry participants driving innovation. Europe also holds a considerable market share, owing to its strong healthcare infrastructure and substantial investments in research and development. Meanwhile, regions with a high incidence of NTDs, particularly those affected by diseases such as leishmaniasis, continue to generate increasing demand for more effective treatment options, contributing to overall market expansion.
Recent Developments:
• In October 2024, Thermo Fisher Scientific Inc., a global leader in science service, unveiled the only fully automated maxi-scale plasmid DNA (pDNA) purification system, the Thermo ScientificTM KingFisherTM PlasmidPro Maxi Processor* (PlasmidPro). With its full automation of small and maxi-scale purification and ability to deliver high-purity plasmids without the need for human column preparation or intervention, PlasmidPro facilitates innovation at scale.
• In August 2024, Merck developed INTerpath-002, a Phase 3 randomized clinical trial that will test V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), along with KEYTRUDA, Merck's anti-PD-1 therapy, as an extra treatment for people with Stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC) that has been completely removed (R0) and has nodal involvement (N2). The INTerpath-002 is now being enrolled by people all over the world.
For Customised Information @ https://www.insightaceanalytic.com/customisation/2928
Segmentation of Neglected Tropical Disease Treatment Market-
By Drug Class-
• Anti-Parasite
• Antifungal
• Antibiotics
• Others
By Disease Type-
• Leishmaniasis
• Schistosomiasis
• Lymphatic Filariasis
• Chagas Disease
• African Trypanosomiasis
• Others
By Distribution Channel-
• Direct Sales
• Indirect Sales
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Get More Information @
https://www.insightaceanalytic.com/report/neglected-tropical-disease-treatment-market/2928
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Official Site Visit: www.insightaceanalytic.com
Tel.: +1 607 400-7072
Email: info@insightaceanalytic.com
Follow US On :
LinkedIn @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Twitter @ https://x.com/MInsightace
YouTube @ https://www.youtube.com/@InsightAceAnalytic
Instagram @https://www.instagram.com/insight_ace_analytic/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neglected Tropical Disease Treatment Market Strategic Insights and Outlook 2026 to 2035 here
News-ID: 4371173 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Automotive Lead Acid Battery Market Strategic Growth Drivers and Outlook 2026 to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Automotive Lead Acid Battery Market Size, Share & Trends Analysis Report By Product (SLI and Micro-Hybrid Batteries), Type (Flooded, Enhanced Flooded, and VRLA), Customer Segment (OEM and Aftermarket), End User (Passenger Car, Light Commercial Vehicles, Heavy Commercial Vehicles, Two-Wheeler, and Three-Wheeler), and Application (Hybrid Vehicles, Electric Vehicles, Light Motor Vehicles, and Heavy Motor Vehicles)- Market…
Automotive Interior Market Investment Opportunities and Forecast 2026 to 2035
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Automotive Interior Market- (By Component Type (Center Stack, Head-up Display, Instrument Cluster, Rear Sear Entertainment, Dome Module, Headliner, Seat, Interior Lighting Door Panel, Center Console, Adhesives & Tapes, Upholstery, Others), By Material (Leather, Fabric, Vinyl, Wood, Glass Fiber Composite, Carbon Fiber Composite, Metal), By Level of Autonomy (Semi-Autonomous, Autonomous, Non-Autonomous),By Electric Vehicle (Battery Electric Vehicle…
Artificial General Intelligence Market Future Landscape and Industry Evolution 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Artificial General Intelligence (AGI) Market - (By Type of Offering (Hardware, Software and Service), Type of Technology (Machine Learning, Deep Learning, Natural Language Processing and Robotics), Mode of Deployment (Cloud-based, On Premise and Web-based), Type of AI (Weak AI, Strong AI and Superintelligence), Type of Processing (Image, Text and Voice Processing), Company Size (SMEs and…
Allogenic Cell Therapies Market Revenue Trends and Growth Potential 2026 to 2035
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Allogenic Cell Therapies Market- by Cell Type(Cardiosphere-Derived Cells (CDCs), Fibroblasts, T-cells, Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs) and Others),Tissue Source(Skin, Blood, PBC, BM and Others), Indication (Acute graft-versus-host disease (GVHD), Chronic Ulcers and Diabetic Foot Ulcers, Osteoarthritis, Crohn's Disease, Cardiovascular Disease, Solid Tumors/Cancers and Others (Alzheimer's Disease, etc.)), Trends, Industry Competition Analysis, Revenue…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
